PortfoliosLab logoPortfoliosLab logo
SBIO vs. XPH
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

SBIO vs. XPH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Pharmaceuticals ETF (XPH). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, SBIO achieves a -0.39% return, which is significantly lower than XPH's 0.66% return. Over the past 10 years, SBIO has outperformed XPH with an annualized return of 8.02%, while XPH has yielded a comparatively lower 3.44% annualized return.


SBIO

1D
1.41%
1M
-7.56%
YTD
-0.39%
6M
3.05%
1Y
65.41%
3Y*
17.80%
5Y*
2.68%
10Y*
8.02%

XPH

1D
1.10%
1M
-4.74%
YTD
0.66%
6M
4.44%
1Y
37.98%
3Y*
13.07%
5Y*
3.50%
10Y*
3.44%
*Multi-year figures are annualized to reflect compound growth (CAGR)

SBIO vs. XPH - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
SBIO
ALPS Medical Breakthroughs ETF
-0.39%55.07%3.81%8.68%-28.08%-17.55%21.17%50.30%-11.81%45.67%
XPH
SPDR S&P Pharmaceuticals ETF
0.66%31.60%4.94%2.97%-9.83%-10.54%14.68%25.61%-15.32%12.05%

Correlation

The correlation between SBIO and XPH is 0.82, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.82

Correlation (3Y)
Calculated over the trailing 3-year period

0.77

Correlation (5Y)
Calculated over the trailing 5-year period

0.78

Correlation (10Y)
Calculated over the trailing 10-year period

0.78

Correlation (All Time)
Calculated using the full available price history since Jan 2, 2015

0.79

The correlation between SBIO and XPH has been stable across timeframes, ranging from 0.77 to 0.82 - a consistent structural relationship.

SBIO vs. XPH - Sectors Allocation Comparison


Sectors
SBIO
XPH

Healthcare

100.0%
100.0%

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Industrials

-

-

Real Estate

-

-

Technology

-

-

Utilities

-

-

Financial Services

-0.0%

-

Healthcare

SBIO
100.0%
XPH
100.0%

Basic Materials

SBIO

-

XPH

-

Communication Services

SBIO

-

XPH

-

Consumer Cyclical

SBIO

-

XPH

-

Consumer Defensive

SBIO

-

XPH

-

Energy

SBIO

-

XPH

-

Industrials

SBIO

-

XPH

-

Real Estate

SBIO

-

XPH

-

Technology

SBIO

-

XPH

-

Utilities

SBIO

-

XPH

-

Financial Services

SBIO
-0.0%
XPH

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

SBIO vs. XPH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SBIO
SBIO Risk / Return Rank: 7272
Overall Rank
SBIO Sharpe Ratio Rank: 6767
Sharpe Ratio Rank
SBIO Sortino Ratio Rank: 6767
Sortino Ratio Rank
SBIO Omega Ratio Rank: 5959
Omega Ratio Rank
SBIO Calmar Ratio Rank: 8888
Calmar Ratio Rank
SBIO Martin Ratio Rank: 7979
Martin Ratio Rank

XPH
XPH Risk / Return Rank: 5555
Overall Rank
XPH Sharpe Ratio Rank: 5151
Sharpe Ratio Rank
XPH Sortino Ratio Rank: 5151
Sortino Ratio Rank
XPH Omega Ratio Rank: 4646
Omega Ratio Rank
XPH Calmar Ratio Rank: 6464
Calmar Ratio Rank
XPH Martin Ratio Rank: 6363
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SBIO vs. XPH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Pharmaceuticals ETF (XPH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


SBIOXPHDifference
Sharpe ratioReturn per unit of total volatility

+0.47

Sortino ratioReturn per unit of downside risk

+0.59

Omega ratioGain probability vs. loss probability

1.36

1.30

+0.06

Calmar ratioReturn relative to maximum drawdown

5.19

3.19

+2.01

Martin ratioReturn relative to average drawdown

15.57

11.37

+4.19

SBIO vs. XPH - Sharpe Ratio Comparison

The current SBIO Sharpe Ratio is 2.24, which is comparable to the XPH Sharpe Ratio of 1.77. The chart below compares the historical Sharpe Ratios of SBIO and XPH, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


SBIOXPHDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

2.24

1.77

+0.47

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.08

0.17

-0.09

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.24

0.16

+0.09

Sharpe Ratio (All Time)

Calculated using the full available price history

0.21

0.38

-0.17

Drawdowns

SBIO vs. XPH - Drawdown Comparison

The maximum SBIO drawdown since its inception was -63.06%, which is greater than XPH's maximum drawdown of -48.03%. Use the drawdown chart below to compare losses from any high point for SBIO and XPH.


Loading charts...

Drawdown Indicators


SBIOXPHDifference

Max Drawdown

Largest peak-to-trough decline

-63.06%

-48.03%

-15.03%

Max Drawdown (1Y)

Largest decline over 1 year

-12.66%

-11.97%

-0.69%

Max Drawdown (3Y)

Largest decline over 3 years

-42.44%

-23.57%

-18.87%

Max Drawdown (5Y)

Largest decline over 5 years

-53.10%

-31.63%

-21.47%

Max Drawdown (10Y)

Largest decline over 10 years

-63.06%

-35.97%

-27.09%

Current Drawdown

Current decline from peak

-16.79%

-7.22%

-9.57%

Average Drawdown

Average peak-to-trough decline

-28.45%

-17.25%

-11.20%

Ulcer Index

Depth and duration of drawdowns from previous peaks

4.22%

3.35%

+0.87%

Volatility

SBIO vs. XPH - Volatility Comparison

ALPS Medical Breakthroughs ETF (SBIO) has a higher volatility of 9.48% compared to SPDR S&P Pharmaceuticals ETF (XPH) at 7.03%. This indicates that SBIO's price experiences larger fluctuations and is considered to be riskier than XPH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


SBIOXPHDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.48%

7.03%

+2.45%

Volatility (6M)

Calculated over the trailing 6-month period

22.70%

16.77%

+5.93%

Volatility (1Y)

Calculated over the trailing 1-year period

29.42%

21.52%

+7.90%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

33.56%

20.84%

+12.72%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

33.17%

22.10%

+11.07%

SBIO vs. XPH - Expense Ratio Comparison

SBIO has a 0.50% expense ratio, which is higher than XPH's 0.35% expense ratio.


Dividends

SBIO vs. XPH - Dividend Comparison

SBIO has not paid dividends to shareholders, while XPH's dividend yield for the trailing twelve months is around 0.66%.


PositionTTM20252024202320222021202020192018201720162015
SBIO
ALPS Medical Breakthroughs ETF
0.00%0.00%3.55%0.22%0.00%0.00%0.00%0.04%2.79%1.77%0.00%0.00%
XPH
SPDR S&P Pharmaceuticals ETF
0.66%0.83%1.58%1.28%1.64%0.95%0.47%0.64%0.65%0.67%0.63%7.15%

Frequently Asked Questions


SBIO and XPH have a correlation of 0.82, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

SBIO has higher volatility (9.48%) compared to XPH (7.03%). In terms of maximum drawdown, SBIO dropped -63.06% vs XPH's -48.03%.

On 10-year performance, SBIO leads with 8.02% vs 3.44% for XPH. On fees, XPH is cheaper at 0.35% per year. On volatility, XPH has been the lower-risk option at 7.03%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 10-year period, SBIO has performed better with a 8.02% return vs 3.44%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

XPH is cheaper with a 0.35% expense ratio, compared with 0.50% for SBIO.

XPH has the higher dividend yield at 0.66%, compared with 0.00% for SBIO.

SBIO tracks S-Network Medical Breakthroughs Index, while XPH tracks S&P Pharmaceuticals Select Industry Index. They also come from different issuers: SS&C and State Street. Their fees differ too: 0.50% for SBIO and 0.35% for XPH.

SBIO currently has the higher Sharpe Ratio (2.24 vs 1.77), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for SBIO and XPH

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer